ReviewJournal of clinical and translational hepatology2015
Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review.
Review in Journal of clinical and translational hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Annals of internal medicine · 2017Pooled it
- Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2021Article
- Hepatitis C Virus Vaccine: Challenges and Prospects.Vaccines · 2020Review
- Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy.Journal of clinical and translational hepatology · 2019Article
- Era of direct acting anti-viral agents for the treatment of hepatitis C.World journal of hepatology · 2018Review
- Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting.International journal of hepatology · 2018Article
- Increased survival in hepatitis c patients who underwent living donor liver transplant: a case-control study with propensity score matching.Annals of surgical treatment and research · 2017Article
- A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients.Scientific reports · 2017Article
- Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection.Clinical and molecular hepatology · 2016Article
- [Strategies in clinical diagnosis and treatment of steroid-resistant acute rejection after orthotopic liver transplantation].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016Article
- Late liver function test abnormalities post-adult liver transplantation: a review of the etiology, investigation, and management.Hepatology international · 2016Review
- Newer therapeutics for hepatitis C.Annals of translational medicine · 2016Article
- The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation.International journal of health sciencesArticle
- Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with hepatitis C virus (HCV) is a common cause of chronic liver disease, and HCV-related cirrhosis and hepatocellular carcinoma are the leading causes for liver transplantation in the Western world. Recurrent infection of the transplanted liver allograft is universal in patients with detectable HCV viremia at the time of transplant and can cause a spectrum of disease, ranging from asymptomatic chronic infection to an aggressive fibrosing cholestatic hepatitis. Recurrent HCV is more aggressive in the post-transplant population and is a leading cause of allograft loss, morbidity, and mortality. Historically, treatment of recurrent HCV has been limited by low rates of treatment success and high side effect profiles. Over the past few years, promising new therapies have emerged for the treatment of HCV that have high rates of sustained virological response without the need for interferon based regimens. In addition to being highly effective, these treatments have higher rates of adherence and a lower side effect profile. The purpose of this review is to summarize current therapies in recurrent HCV infection, to review the recent advances in therapy, and to highlight areas of ongoing research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.